News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 28, 2017
London, UK and Carlsbad, CA, 28 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today an
Dec 21, 2017
London, UK, 21 Dec 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appoi
Dec 13, 2017
- Previous License Agreement with Otsuka Terminated -
Dec 11, 2017
LONDON, UK, 11 December 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the
Dec 06, 2017
London, UK, 6 December 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public
Dec 05, 2017
London, UK, 5 December 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to m
Dec 04, 2017
- Epidiolex® (cannabidiol) NDA Submitted to FDA – - Conference call today at 7:30 a.m. EST -
Nov 27, 2017
London, UK, 27 November 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 4 December, 2017 i
Nov 22, 2017
- 29th Annual Piper Jaffray Healthcare Conference on November 29, 2017 - - Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on November 30, 2017 -
Nov 21, 2017
- Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program -

Pages